ATE359779T1 - Selbstemulgierende systeme zur abgabe von taxoiden - Google Patents

Selbstemulgierende systeme zur abgabe von taxoiden

Info

Publication number
ATE359779T1
ATE359779T1 AT03710117T AT03710117T ATE359779T1 AT E359779 T1 ATE359779 T1 AT E359779T1 AT 03710117 T AT03710117 T AT 03710117T AT 03710117 T AT03710117 T AT 03710117T AT E359779 T1 ATE359779 T1 AT E359779T1
Authority
AT
Austria
Prior art keywords
self
taxoids
delivery
emulsifying systems
water
Prior art date
Application number
AT03710117T
Other languages
English (en)
Inventor
Gregory Lambert
Alain Razafindratsita
Jean-Sebastien Garrigue
Shicheng Yang
Neslihan Gursoy
Simon Benita
Original Assignee
Novagali Pharma Sa
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02290513A external-priority patent/EP1340497A1/de
Application filed by Novagali Pharma Sa, Yissum Res Dev Co filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of ATE359779T1 publication Critical patent/ATE359779T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cash Registers Or Receiving Machines (AREA)
AT03710117T 2002-03-01 2003-02-28 Selbstemulgierende systeme zur abgabe von taxoiden ATE359779T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36109002P 2002-03-01 2002-03-01
EP02290513A EP1340497A1 (de) 2002-03-01 2002-03-01 Selbstemulgierende Systeme zur Abgabe von schwerlöslichen Arzneimitteln

Publications (1)

Publication Number Publication Date
ATE359779T1 true ATE359779T1 (de) 2007-05-15

Family

ID=27790109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03710117T ATE359779T1 (de) 2002-03-01 2003-02-28 Selbstemulgierende systeme zur abgabe von taxoiden

Country Status (10)

Country Link
US (1) US20050232952A1 (de)
EP (1) EP1480636B1 (de)
JP (1) JP2005523295A (de)
AT (1) ATE359779T1 (de)
AU (1) AU2003214538A1 (de)
CA (1) CA2478424A1 (de)
DE (1) DE60313299T2 (de)
ES (1) ES2283756T3 (de)
IL (1) IL163808A0 (de)
WO (1) WO2003074027A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
EP1498120A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Halbfeste Formulierung für die orale Verabreichung des Taxols
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
WO2008042841A2 (en) * 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Docetaxel compositions
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
KR20100023862A (ko) * 2007-06-22 2010-03-04 싸이도우스 엘엘씨. 트윈 80을 함유하지 않은 도세탁셀의 용해 제제
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
WO2009123595A1 (en) * 2008-04-04 2009-10-08 Robert Shorr Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
JP5868414B2 (ja) 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド タキソイドの医薬組成物
BR112014029188B1 (pt) 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
EP3424493A1 (de) * 2017-07-07 2019-01-09 SolMic Research GmbH Stabile cannabinoide zusammensetzungen
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49746A1 (en) * 1992-08-28 1998-06-15 Pharmos Corp Submicron emulsions as ocular drug delivery vehicles
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5627209A (en) * 1993-12-15 1997-05-06 Alcon Laboratories, Inc. Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
US5567424A (en) * 1994-06-10 1996-10-22 Reliv International, Inc. Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
AU5736096A (en) * 1995-05-15 1996-11-29 Sabinsa Corporation A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy cit ric acid
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
US5716976A (en) * 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
NZ502569A (en) * 1997-07-29 2002-05-31 Upjohn Co Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4
US6160172A (en) * 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
WO2000012080A1 (en) * 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6447807B1 (en) * 1999-09-14 2002-09-10 Dallas L. Clouatre Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6399089B1 (en) * 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
US6476071B1 (en) * 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6482858B1 (en) * 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6441041B1 (en) * 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US6638542B2 (en) * 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
WO2003092730A1 (en) * 2002-04-30 2003-11-13 Unibar Corporation Hydroxycitric acid salt composition and method of making
TW200427447A (en) * 2003-03-21 2004-12-16 Interhealth Nutraceuticals Inc Method and composition for decreasing ghrelin levels

Also Published As

Publication number Publication date
AU2003214538A1 (en) 2003-09-16
WO2003074027A3 (en) 2003-12-18
EP1480636A2 (de) 2004-12-01
DE60313299D1 (de) 2007-05-31
WO2003074027A2 (en) 2003-09-12
IL163808A0 (en) 2005-12-18
WO2003074027A8 (en) 2004-10-07
EP1480636B1 (de) 2007-04-18
US20050232952A1 (en) 2005-10-20
JP2005523295A (ja) 2005-08-04
DE60313299T2 (de) 2008-01-03
ES2283756T3 (es) 2007-11-01
CA2478424A1 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
ATE359779T1 (de) Selbstemulgierende systeme zur abgabe von taxoiden
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
CO5580835A2 (es) Nuevas formulaciones analogas de ciclosporina
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
MX2012014443A (es) Composiciones oftalmicas para la administracion de ingredientes activos liposolubles.
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
SE0003449D0 (sv) Anticancer compositions
DE60326455D1 (de) En arzneimittels
ECSP085181A (es) Sistema de administración de fármacos que comprende rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EA200601724A1 (ru) Новые композиции для местной доставки
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NO20024272D0 (no) Nytt selvemulgerende legemiddelavleveringssystem
BR0215187A (pt) Composições farmacêuticas que compreendem uma ciclosporina, um tensoativo hidrofìlico e um tensoativo lipofìlico
DK1073467T3 (da) Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D
EE200200483A (et) Uus iseemulgeeruv ravimi manustamise süsteem
ATE289801T1 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
DE60239752D1 (de) Den geschmack verdeckende auslaufsichere formulierung
AR038858A1 (es) Combinacion
DK1653923T3 (da) Oral afleveringssystem omfattende en bivæsket skum
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DE60319802D1 (de) Sedierende nicht-benzodiazepin-formulierungen
ECSP003551A (es) Complejo farmaceutico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties